Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC By Ogkologos - September 3, 2026 48 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5-year follow-up analysis of the KEYNOTE-564 study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable... April 12, 2022 FDA Approves First Adenoviral Vector-Based Gene Therapy for High-Risk Bacillus Calmette-Guérin... January 19, 2023 Targeted Drug Combo May Change Care for Rare Brain Tumor Craniopharyngioma August 10, 2023 FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase for Newly Diagnosed... January 22, 2021 Load more HOT NEWS Finding Hope in the New Year During COVID-19 and Cancer European Lung Cancer Congress 2025, Paris, France, 26-29 March 2025 COVID-19, Vaccines, and the Immune System: Emerging Research from NCI’s SeroNet EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan
